Biotech stocks have had a great run-up over the past year, but it's the biggest names in this sector that are providing investors with a double dose of reliability and growth. Big biotech stocks like Biogen Idec (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) have thrived behind blockbuster drugs, and both companies reported earnings for the past quarter this week.
Amgen's recent earnings report didn't surprise many investors used to stellar quarters from this company, as its net profit for the fourth quarter climbed 30% year over year. Meanwhile, Biogen's profits also roared higher in its most recent quarter, fueled by both veteran blockbuster drugs and ballyhooed new therapies the company's hoping will emerge as the blockbusters of the future.
But which company came out on top this earnings season? In the video below, Motley Fool contributor Dan Carroll compares Biogen and Amgen's recent results and talks about how the two stocks stack up for investors going into the rest of 2014.
The new biotech boom poised to reap big profits
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.